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Disruption of the with no lysine kinase^STE20-
proline alanine-rich kinase pathway reduces the
hypertension induced by angiotensin II
Luz G. Cervantes-Pereza, Maria Castaneda-Buenob, Jose V. Jimenezb, Norma Vazquezd,
Lorena Rojas-Vegab, Dario R. Alessic, Norma A. Bobadillab,d, and Gerardo Gambab,d
Objective: The hypertensive effect of angiotensin II
(AngII), a peptide hormone, is dependent on its intrarenal
actions and the activation of the renal Na–Cl cotransporter
(NCC), by AngII requires integrity of the with no lysine
kinase/STE20-proline alanine-rich kinase (WNK/SPAK)
signaling pathway. Here, we analyzed if the integrity of
the WNK/SPAK pathway is required for AngII infusion to
induce arterial hypertension.
Methods: We tested the effect of AngII or aldosterone
administration on the blood pressure and on pNCC/NCC
ratio in SPAKT243A/243A knock-in mice in which the
kinase and thus NCC cannot be activated by WNK kinases.
AngII or aldosterone was infused at 1440 or 700mg/kg per
day, respectively, for 14 days using osmotic minipumps.
The aldosterone-treated mice were exposed to NaCl
drinking water (1%) during the hormone administration.
The arterial blood pressure was assessed using
radiotelemetry.
Results: We observed that in the SPAK knock-in mice, the
AngII-induced hypertensive effect was significantly reduced
and associated with an absence of AngII-induced NCC
phosphorylation. In contrast, the hypertensive effect of
aldosterone was enhanced and was related with an
increased response to amiloride, but not to thiazide-type
diuretics, without a significant increase in NCC
phosphorylation.
Conclusion: Our data suggest that AngII-induced
hypertension requires, at least partly, NCC activation via
the WNK/SPAK signaling pathway, whereas aldosterone-
induced hypertension depends on epithelial sodium
channel activation in a WNK/SPAK-independent manner.
SPAK knock-in mice emerge as a useful model to
distinguish between the effects of AngII and aldosterone
on distal nephrons.
Keywords: aldosterone, distal convoluted tubule, salt
transport, thiazide, with no lysine kinase 4
Abbreviations: CD, collecting duct; DCT, distal
convoluted tubule; ENaC, epithelial sodium channel; NCC,
Na–Cl cotransporter; SPAK, STE20-proline alanine-rich
kinase; WNK, with no lysine kinase
INTRODUCTION
T
he arterial hypertension (AH) induced by angioten-
sin II (AngII) infusion depends on the intrarenal
action of this hormone. The absence of AT1 exclu-
sively in the kidney precludes the increase in blood pres-
sure (BP) induced by AngII infusions using osmotic
minipumps [1]. In the wild-type mice, this increase is
associated with increased salt retention [2]. The absence
of the intrarenal expression of angiotensin-converting en-
zyme also precludes the AngII-induced hypertension, sug-
gesting that infused AngII induces the activation of the
intrarenal renin angiotensin system; this activation then
promotes salt retention and hypertension [3]. In addition,
it has been shown that the salt retention and hypertension
associated with AngII infusion is caused by increased salt
reabsorption in the distal convoluted tubule (DCT) and the
collecting duct [4,5].
The major salt transport pathway in the DCT is the
thiazide-sensitive Na–Cl cotransporter (NCC). The NCC
activation is associated with the phosphorylation of key
threonine residues located in its amino terminus [6] by the
Ste20-related proline–alanine-rich kinase (SPAK) [7]. In
turn, this kinase is activated by the with no lysine kinases
(WNKs) through WNK-induced phosphorylation of the
threonine 243 and serine 383 of SPAK [8]. Mutation of
threonine 243 in the SPAKT243A/T243A knock-in mice
(SPAK-KI) precludes the activation of SPAK by WNKs
and results in a decreased effect of SPAK on the NCC;
these mice display Gitelman-like phenotype, which is
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associated with a basal reduction of NCC expression and
phosphorylation levels [9]. In addition, the Mendelian dis-
ease known as familial hyperkalemic hypertension (FHH)
or pseudohypoaldosteronism type II is caused bymutations
in two different serine/threonine kinases, WNK1 and
WNK4, and in two genes encoding the proteins KLHL3
and CUL3 that form a ring-type E3-ubiquitin ligase that
targets WNK kinases for ubiquitylation and degradation
[10–12]. Mutations in any of these genes result in increased
expression of WNKs, which causes increased activity of the
NCC via activation of the SPAK-induced phosphorylation
of this cotransporter [13,14]. We have previously shown
in vitro and in vivo that the presence ofWNK4 is required to
achieve the NCC activation by AngII [15,16], which mod-
ulates WNK4 activity and phosphorylation via a protein
kinase C (PKC)-related mechanism [17]. These observations
strongly suggest that the AngII effect on the NCC requires
the integrity of the WNK4–SPAK–NCC pathway. Here,
we present evidence that AngII-induced AH is, at least
partly, dependent on the activation of the NCC by the
WNK–SPAK pathway.
METHODS
Experimental protocol
SPAK-KI mice were previously generated and characterized
[9]. The experimental protocols were conducted in 12–16-
week old (approximately 25 g) male SPAK-KI mice and
their wild-type littermates, which were bred and main-
tained in the animal facilities of our institution. All experi-
ments were conducted according to the Guide for the Care
and Use of Laboratory Animals and were approved by the
Animal Care Use Committee at our Institutions. Four sepa-
rate experimental designs were followed: first, for telemetry
studies SPAK-wild-type (SPAK-WT) and SPAK-KI mice
were implanted and used as their own controls before
and after AngII or Aldosterone infusion (n¼ 5). Second,
for western blot analysis, SPAK-WT and SPAK-KI mice were
infused with vehicle and compared with SPAK-WT and
SPAK-KI mice infused with AngII or aldosterone (n¼ 5). BP
was monitored by radiotelemetry to confirm the hyper-
tensive effects of drugs. Third, for determining diuretic
response, a single injection with hydrochlorothiazide or
amiloride on SPAK-WT and SPAK-KI mice infused with
AngII or aldosterone was administrated at 13th day of
infusion (n¼ 5). Fourth, for studying diuretic effect on
BP by radiotelemetry, a single doses of amiloride on
SPAK-WT and SPAK-KI mice infused with AngII or aldoste-
rone and with sensor implanted was injected at the 13th day
of infusion (n¼ 5).
Radiotelemetry
The mice were anesthetized using LEI Medical Table Top
Anesthesia Machine for isofluorane (4% for induction and
2.5% for maintenance) (LEI Medical, Portland, Oregon,
USA). An incision was made in the front of the neck, and
the carotid artery was separated from the jugular vein and
the vagus nerve. After the artery was ligated near the head
using 3–0 silk sutures, a small incision was made with a
needle, and the tip of the catheter of the transmitter (model
PA-C10; Data Science International, St. Paul, Minnesota,
USA) was introduced into the vessel and pushed until it was
close to the aortic arch. The catheter was fastened using the
distal silk. To place the transmitter, a subcutaneous pocket
was made. The neck incision was sutured, and the mice
were allowed to recover completely.
Aldosterone and angiotensin II infusion
One week after the implantation of the radiotelemetry
catheter and after 3-day 1-h of basal BP measurements,
subcutaneous osmotic minipumps (model 1002; Alzet,
Cupertino, California, USA) were implanted for the infusion
of AngII (Sigma-Aldrich, St Louis, Missouri, USA) at
1440mg/kg per day or aldosterone (Sigma-Aldrich) at
700mg/kg per day for 14 days. The aldosterone-infused
animals were provided with 1% saline solution as drinking
water from days 0 to 14. The BP was measured using
radiotelemetry (Dataquest A.R.T. system and PhysiolTel
Receivers; Data Science International) every day at
1000 h for at least 1 h, with intervals of 5 s for each determi-
nation, giving 550 measures approximately for each mouse.
During the 48-h period of continuous basal BP measure-
ments, we determined the optimum time frame for reliable
measurements, which was established for 1 h at 1000 h.
Na–Cl cotransporter expression and
phosphorylation
At the end of the infusion period, the mice were sacrificed,
and kidneys from each group were homogenized in lysis
buffer containing the following: 50mmol/l Tris–HCl (pH
7.5), 1mmol/l ethylene-bis(oxyethylenenitrilo)tetraacetic
acid, 1mmol/l ethylenediaminetetraacetic acid, 50mmol/l
sodium fluoride, 5mmol/l sodium pyrophosphate, 1mmol/l
sodium orthovanadate, 1% (wt/vol) Nonidet P-40 (Sigma-
Aldrich), 0.27mol/l sucrose, 0.1% (vol/vol) 2-b-mercaptoe-
thanol and protease inhibitors (Complete tablets; Co-Ro
Roche, Sigma-Aldrich). Sixty micrograms from each homog-
enatewere resolved into 10% SDS–PAGE and transferred for
1 h to polyvinylidene difluoride membranes. Membranes
were blocked in 10% skim milk and incubated overnight
with sheep antipNCC (T60) antibody, and after stripping,
theywere incubatedwith anti-NCC antibody, both produced
by Dario Alessi from Phosphorylation Research Unit (Dun-
dee, Scotland, United Kingdom) that were previously used
and characterized by our group [7,18] and anti b-actin (Santa
Cruz Biotechnology Inc, Dallas, Texas, USA) antibodies. For
densitometric analysis purpose, total NCC and pNCC were
normalized with b-actin, then, total pNCC/NCC ratio
was calculated.
Diuretic challenge
Another group of five SPAK-WT and five SPAK-KI mice
were infused with AngII or aldosterone/NaCl 1% for
14 days. On ninth day, the mice were placed in metabolic
cages for 3 days for acclimation. On 12th day, urine samples
were collected for measuring basal sodium excretion. The
next day (13th day), a single intraperitoneal (i.p.) injection
of amiloride (Sigma-Aldrich) (5mg/kg) or hydrochlorothi-
azide (Sigma-Aldrich) (50mg/kg) was applied, and urine
was collected 4 or 6 h, respectively, after diuretic injection
and until 24 h for urinary sodium determination. Both
collections were independent. Urine volume at 4 and 6h
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was enough to measure electrolytes because we adminis-
trate a diuretic.
Diuretic effect on blood pressure in
angiotensin II and aldosterone-infused-mice
Different groups of five SPAK-WT and five SPAK-KI mice
were implanted with radiotelemetry sensors and infused
with AngII or aldosterone and 1% NaCl in drinking water.
After 13 days of infusion, the mice were challenged
with a single injection of amiloride (5mg/kg). BP was
measured continuously for 2 h before and 12h after ami-
loride injection.
Plasma and urinary determinations
Plasma and urinary samples were diluted 1 : 1 with distilled
water and placed into an autoanalyzer (Technicon RA-1000;
Bayer, Tarrytown, New York, USA) for sodium, potassium
and creatinine determinations.
Statistics
All values represent the mean and the standard error for
each experimental value. One-way or repeated measure-
ments analysis of variance were performed to analyze the
difference between the groups. The data were significant
for P less than 0.05.
RESULTS
The hypertensive effect of angiotensin II is
reduced in Ste20-related proline–alanine-rich
kinase-knock-in mice
Figure 1 shows the average of SBP (Fig. 1a) and mean BP
(Fig. 1b) values observed during the 3-day 1-h previous to
AngII infusion at baseline and in the last 3 days of AngII
administration by the osmotic minipump (days 12, 13
and 14). In the basal period, the SBP was 118 4.6 and
112 9.5mmHg and the mean BP was 98 1.6 and
95 7.2mmHg in the wild-type and SPAK-KI mice, respec-
tively. The differences were NS. Thus, we did not observe
the difference in BP in the SPAK-KI mice as reported
previously by Rafiqi et al. [9]. In that work, however, the
mean BP observed in the SPAK-KI mice was similar to our
data, around 96mmHg, while the mean BP of control mice
was higher, around 105mmHg.
As depicted in Fig. 1, at the end of the AngII infusion
period, the SBP and mean BP were significantly higher in
the wild type than in SPAK-KI animals. SBP were 171 0.3
and 147 2.0mmHg and mean BP were 148 6.1 and
131 1.0mmHg for wild-type and SPAK-KI mice, respec-
tively. The increment of BP in wild-type animals was about
50mmHg, whereas in the SPAK-KI mice was about
35mmHg. Thus, BP increase in SPAK-KI mice was about
35% lower than in wild-type mice.
The Na–Cl cotransporter response to
angiotensin II is abrogated in Ste20-related
proline–alanine-rich kinase-knock-in mice
As previously shown [9], the NCC basal expression and
phosphorylation levels are lower in SPAK-KI mice than in
their corresponding littermates. We analyzed the effect of
vehicle or AngII infusion on NCC expression and phos-
phorylation levels (Fig. 2). AngII induced a significant
increase in the pNCC/NCC ratio in the wild-type mice. In
contrast, no effect was observed in the SPAK-KImice. These
observations suggest that NCC phosphorylation and the
hypertensive effect of AngII are blunted in the kidneys of
the SPAK-KI mice.
The hypertensive effect of aldosterone is
increased in Ste20-related proline–alanine-rich
kinase-knock-in mice
We also analyzed the effect of aldosterone administration
and a high-salt diet on the BP of wild-type and SPAK-KI
mice. Figure 3 shows the mean for BP in the basal state and
after 14 days of aldosterone administration, similar to the
analysis showed in Fig. 1. SBP in wild-type mice increased
from 109 7.2 to 126 3.8mmHg, that is an increment of
about 15mmHg. In contrast, in the SPAK-KI mice, the
observed increase was from 105 2.7 to 143 3.4mmHg,
for a difference of about 38mmHg. Similar difference was
observed for the mean BP. Thus, opposite to the observa-
tions for AngII, SPAK-KI mice were more sensitive than
wild-type mice in response to aldosterone.
As expected, we observed an increase in the pNCC/total
NCC ratio in the wild-type mice (Fig. 4a and b) that was
likely due to the hypokalemia induced by aldosterone
infusion (Fig. 4c). In contrast, the increased in pNCC did
not occur in the SPAK-KI mice treated with aldosterone,
FIGURE 1 The arterial hypertension induced by angiotensin II infusion is blunted in Ste20-related proline–alanine-rich kinase-knock-in mice. (a) SBP and (b) mean blood
pressure. Graphs represent SBP and mean blood pressure average of 3-day 1-h measures before angiotensin II infusion (basal) and the average of 12th, 13th and 14th-day
1-h after angiotensin II infusion (14-day) of wild-type (white bars) and Ste20-related proline–alanine-rich kinase-knock-in (black bars) mice. Blood pressure was assessed
using radiotelemetry every day from 100 to 1100 h, during 17 days (before and after angiotensin II infusion). Each bar represents the mean standard error of
approximately 550 measures of each mouse. n¼5 mice for each group. P less than 0.05 wild-type vs. Ste20-related proline–alanine-rich kinase-knock-in.
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despite a similar reduction in plasma potassium, support-
ing, as has been previously shown, that with no lysine
kinase/STE20-proline alanine-rich kinase (WNK/SPAK)
pathway is also required to achieve the NCC phosphory-
lation due to hypokalemia [19,20].
Na–Cl cotransporter and epithelial sodium
channel involvement in the hypertensive effect
of aldosterone in Ste20-related proline–
alanine-rich kinase-knock-in
To analyze the activated pathway associated with the effect
of aldosterone, we used the wild-type and SPAK-KI mice
infused with aldosterone and measured the diuretic
response to a single injection i.p. of hydrochlorothiazide
or amiloride, which are well known blockers of the NCC
and the epithelial Naþ channel, epithelial sodium channel
(ENaC), respectively. As shown in Fig. 5, the natriuretic
response to amiloride was significantly higher in the
SPAK-KI mice than in the wild-type mice. In contrast, the
response to the thiazide diuretic was higher in the wild-
type mice than in the SPAK-KI mice. These results suggest
that the hypertensive effect of aldosterone in SPAK-KI mice
was associated with ENaC activation, rather than NCC
activation. We then proceeded to further analyze the role
of ENaC in the development of hypertension in the SPAK-KI
mice. We tested the effect of amiloride administration in BP
after 10 days of aldosterone infusion in both SPAK-KI and
wild-type mice. During the first 5 h after i.p. injection of
amiloride, a marked reduction in SBP was observed in the
SPAK-KI group (140–105mmHg) but not in the wild-type
mice (Fig. 6). This effect was attenuated in the following
hours, consistent with the marked decrease in amiloride-
induced natriuresis observed after the initial hours of dos-
age. Nevertheless, a lower SBP was maintained compared
with the baseline measurements registered during aldoste-
rone infusionwithout amiloride. This phenomenonwas not
observed in the wild-type group. The amiloride injection on
SPAK-KI and wild-type mice infused with AngII did not
show any effect on BP (Supplementary Fig. 1, http://link-
s.lww.com/HJH/A843).
DISCUSSION
It is known that AngII-induced increase in arterial BP is due
to the intrarenal effects of this peptide hormone [2] and
several lines of evidence suggest that NCC activation could
be responsible, at least partly, for the increased salt reab-
sorption that precedes the development of hypertension in
mice infused with AngII [2]. We have proposed that
the AngII effect on the NCC requires the integrity of the
WNK-SPAK pathway. By using Xenopus laevis oocytes as an
expression system, we observed that the activation of NCC
by AngII requires the presence of WNK4 [15]. In mpkDCT
cells, AngII induced an increase in the phosphorylation of
both the SPAK and the NCC [15,21]. Then, we demonstrated
that the SPAK phosphorylation induced by a low-salt diet or
AngII in wild-type mice was not observed in the WNK4
knockout mice, suggesting that the presence of WNK4 is
required for AngII to induce SPAK–NCC phosphorylation
FIGURE 2 Angiotensin II infusion induced an increase in Na–Cl cotransporter
expression and phosphorylation in wild-type, but not in Ste20-related proline–ala-
nine-rich kinase-knock-in mice. (a) Representative western blot for total Na–Cl
cotransporter, phosphor-Na–Cl cotransporter and b-Actin from proteins extracted
from the kidney of wild-type or Ste20-related proline–alanine-rich kinase-knock-in
mice infused with vehicle or angiotensin II, as stated. (b) Densitometric analysis of
two independent western blot for total Na–Cl cotransporter and phosphor-Na–Cl
cotransporter expressed as the pNa–Cl cotransporter/total Na–Cl cotransporter
ratio after b-actin normalization. Open bars indicate vehicle infusion and closed
bars indicate angiotensin II infusion. P less than 0.0001 vs. all other groups.
FIGURE 3 The effect in blood pressure induced by aldosterone infusion was higher in Ste20-related proline–alanine-rich kinase-knock-in mice. (a) SBP and (b) mean blood
pressure. Graphs represent SBP and mean blood pressure average of 3-day 1-h measures before aldosterone infusion (basal) and the average of 12th, 13th and 14th-day
1-h after aldosterone infusion (14-day) of wild type (white bars) and Ste20-related proline–alanine-rich kinase-knock-in (black bars) mice. Blood pressure was assessed
using radiotelemetry every day from 1000 to 1100 h, during 17 days (before and after aldosterone infusion). Each bar represents the mean standard error of approxi-
mately 550 measures of each mouse of each day. n¼5 mice for each group. P less than 0.05 vs. Ste20-related proline–alanine-rich kinase-knock-in.
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[16]. Supporting that AngII effects on DCT require the
presence of WNK4, it was observed that AngII, via the
PKC pathway, induces KLHL3 phosphorylation in the serine
433 precluding the effect of KLHL3–CUL3 complex on
WNK4 and thus, preventing WNK4 ubiquitylation and
its destruction [22]. Furthermore, the disruption of the
SPAK-NCC cascade via crossing WNK4D561A/ mice (which
recapitulate a FHH phenotype) with SPAK/ mice has
been proven to correct the hypertensive and hyperkalemic
phenotype associated with NCC hyperactivity [23]. Most
recently, we have shown that AngII via PKC phosphory-
lates WNK4 in key residues increasing the activity of the
kinase toward SPAK and NCC [17]. Given these lines of
evidence, we used SPAK-KI mice to assess the role of the
WNK4–SPAK–NCC pathway in the AngII-induced increase
in BP [8].
Our results suggest that, indeed, the AngII-induced
hypertension is at least partly dependent on the NCC
activation via the SPAK pathway. AngII infusion using a
minipump with pressor dose was associated with increased
phosphorylation of the NCC in wild-type mice. In contrast,
the absence of SPAK activity precluded the phosphoryla-
tion of NCC by AngII. Radiotelemetry measurements of BP
revealed that AngII-induced hypertension was partially
blunted in SPAK-KI mice. The BP still increased, indicating
that there are other pathways in the kidney through AngII
induces hypertension in addition to the activation of SPAK-
NCC. One possibility is that the activation of ENaC plays a
FIGURE 5 Diuretic challenge with hydrochlorothiazide or amiloride in STE20-proline alanine-rich kinase-WT and Ste20-related proline–alanine-rich kinase-knock-in mice
infused with aldosterone and 1% NaCl in the drinking water. Mice were kept in a metabolic cage to determine the basal urinary sodium excretion (adjusted per volume as
mEq sodium over mg of creatinine in urine) and the urinary sodium excretion after a single i.p. injection of hydrochlorothiazide (50 mg/kg) or amiloride (5 mg/kg). Bars
represent mean standard error in wild-type (white) and Ste20-related proline–alanine-rich kinase-knock-in (black), before (R0), 4 and 20 h after amiloride administration,
and 6 and 18 h after hydrochlorothiazide administration. n¼5. P less than 0.05 vs. Ste20-related proline–alanine-rich kinase-knock-in at 4, 6 and 18 h.
FIGURE 4 Aldosterone infusion increased the pNa–Cl cotransporter/Na–Cl cotransporter ratio in wild-type mice, but not in Ste20-related proline–alanine-rich kinase-knock-
in mice. (a) Representative western blot for total Na–Cl cotransporter, phosphor-Na–Cl cotransporter and b-actin of proteins extracted from the kidney of wild-type or
Ste20-related proline–alanine-rich kinase-knock-in mice infused with vehicle or Aldosterone, as stated. (b) Densitometric analysis of two independent western blot for total
Na–Cl cotransporter and phosphor-Na–Cl cotransporter, expressed as the pNa–Cl cotransporter/total Na–Cl cotransporter ratio after b-actin normalization. Open bars
indicate vehicle infusion, and closed bars indicate aldosterone infusion. (c) Plasma potassium levels after 13-day treatment with aldosterone or angiotensin II in STE20-
proline alanine-rich kinase-WT and Ste20-related proline–alanine-rich kinase-knock-in mice. n¼5. Open bars show STE20-proline alanine-rich kinase-WT mice and close
bars show Ste20-related proline–alanine-rich kinase-knock-in mice. P less than 0.05 vs. Ste20-related proline–alanine-rich kinase-knock-in basal.
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role in this response to AngII, because this hormone also
increases the activity of this channel [5,24,25]. In addition,
AngII also has positive effects on the proximal tubule
Naþ : Hþ exchanger, NHE3 [26], as well as in the expression
and cleavage of ENaC, both in the cortex and in the medulla
which might also be important for salt reabsorption in this
setting [27].
Another potential mechanism could implicate blood
vessels. It has been suggested that WNK–SPAK pathway
is capable to regulate contractibility of the vessels. It is
known that NKCC1, that is a target of SPAK, is expressed in
vascular smooth muscle cells. Bergaya et al. [28], showed
that reduction of WNK1 expression in the WNK1þ/ pre-
vented phenilephrine-induced vasocontraction of aorta
rings and mesentery vessels. However, AngII-induced vas-
ocontraction was similar between control and WNKþ/
mice, suggesting a specific alpha-adrenergic activation
when the pathway is incomplete [3,28]. Zeniya et al. [29]
showed that KLHL2, homologue of KLHL3, is present in
aorta and vascular smooth muscle cells and AngII dimin-
ished its expression and augmented WNK3 expression [29],
also suggesting the participation of WNKs in vascular tone.
In addition, the SPAK null mice that express a Gitelman-like
phenotype (hypotension, hypokalemia and alkalosis)
exhibits a decrease in the phosphor-NKCC1 in blood ves-
sels [30] and reduced response to phenylephrine, suggest-
ing that activation of NKCC1 by SPAK may play a role on
vasoconstriction. This would explain the differences in BP
in the initial days of AngII treatment, during which the effect
of AngII on BP might not be entirely attributed to NCC
activation. The observation that AngII-induced hyperten-
sion is significantly blunted in the absence of SPAK activity
supports the proposal that strategies preventing SPAK–
NCC interactions could be a new therapeutic avenue for
hypertension [31].
In contrast to the observations made with the AngII
infusion in the current study, we observed a significant
increase in BP in response to the combination of aldoste-
rone and high salt-diet in the SPAK-KI mice. The absence of
aldosterone-induced hypertension in the wild-type mice
might be explained by the C57BL/6J genetic background of
the SPAK-WT and SPAK-KI mice, because C57BL/6J mice
are often resistant to aldosterone/salt treatment [32]. The
SPAK-KI mice, however, developed a significant increase in
BP. After aldosterone infusion, we observed a significantly
higher response to amiloride-induced natriuresis accompa-
nied by marked decrease in arterial BP in SPAK-KI mice. In
contrast, the response to hydrochlorothiazide was higher in
the wild-type mice than in the SPAK-KI mice, consistent
with the lower expression of NCC and pNCC in the SPAK-KI
mice. In fact, the expected increase of pNCC during aldo-
sterone infusion due to the development of hypokalemia
was observed in the wild type, but not in the SPAK-KI mice,
indicating that NCC response to changes in serum potassi-
um also requires the integrity of the WNK/SPAK pathway.
Our observations thus suggest that aldosterone-induced
hypertension in SPAK-KI mice is mostly associated with the
activity of the ENaC in the collecting duct. This is supported
by the observations of Rafiqi et al. [9], who demonstrated
that the expression of all three ENaC subunits was increased
in SPAK-KI mice under normal serum aldosterone levels,
both in regular and low-salt diet. Of note, due to the
decreased expression of NCC and increased expression
of ENaC, SPAK-KI mice are thus resistant to AngII-induced
hypertension, but particularly sensitive to aldosterone-in-
duced hypertension. As a conclusion, the disruption of the
WNK–SPAK pathway attenuates the AH and NCC phos-
phorylation induced by AngII, while it enhances the aldo-
sterone-induced hypertension mediated by ENaC.
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Reviewers’ Summary Evaluations
Reviewer 2
The significance of the present study lies on the differential
novel role of WNK-SPAK pathway in hypertension. The
disruption of the WNKSPAK pathway attenuates the
arterial hypertension and NCC phosphorylation induced
by angiotensin II, while it enhances the aldosterone-
induced hypertension mediated by ENaC. The weaknesses
of the study lie in the lack of exploring deep mechanistic
and see whether the reduction in blood pressure is associ-
ated with vascular and/or heart structure and function
improvement.
Reviewer 3
The authors investigate whether the WNK/SPAK (with no
lysine kinases/Ste20-related proline-alanine-rich kinase) is
required for angiotensin II induced arterial hypertension
using SPAK knock-in with mutation of threonine 243. This
mutation prevents activation of SPAK (SPAK and SPAK-2)
by WNKs, decreasing the effect of SPAK on the thiazide-
sensitive Na–Cl cotransporter. They provide convincing
evidence that angiotensin II dependent hypertension is
partially dependent on this pathway whereas aldoste-
rone-induced hypertension depends on epithelial sodium
channel activation. The study provides novel mechanistic
insights as to how angiotensin II-mediated signaling con-
tributes arterial hypertension but clinical translation may be
limited given the availability of thiazides.
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